Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TTF + Durvalumab + GemCis in unresectable BTC
NCT06611345Recruiting
- Sponsor
- Jiangsu Healthy Life Innovation Medical Technology
- Start
- Oct 2024
- Primary completion
- Oct 2026
- Countries
- 1
01
Overview
Open-label, single-arm trial in biliary tract cancer (BTC), sponsored by Jiangsu Healthy Life Innovation Medical Technology. Primary endpoint: Progression-Free Survival at 24 months. Started Oct 2024; status: recruiting.
02
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT06611345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06611345.